

OMB Number:	3235-0104
Estimated average burden	
hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>Cabell Christopher</u> (Last) (First) (Middle) <u>1000 N. WEST STREET, SUITE 1200</u> (Street) <u>WILMINGTON DE 19801</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>02/21/2025</u>	3. Issuer Name and Ticker or Trading Symbol <u>Inhibikase Therapeutics, Inc. [IKT]</u> 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>President & Head of R&D</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) <u>02/25/2025</u> 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
---	---	---	---

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>1,014,846⁽¹⁾⁽²⁾</u>	<u>D</u>	

Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			

Explanation of Responses:

1. This Form 3 amendment is being filed solely to include shares of common stock which were inadvertently omitted from the original Form 3 filed by the Reporting Person on February 25, 2025.
2. Represents shares of common stock issued to the Reporting Person as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. ("CorHepta") on February 21, 2025 (the "Closing Date") by the Issuer, pursuant to the Agreement and Plan of Merger and Reorganization by and among the Issuer, Project IKT Merger Sub, Inc., CorHepta, and Preston S. Klassen, solely in his capacity as sellers' representative. Of these, 169,141 shares vested on the Closing Date, 507,423 shares shall vest on the first anniversary of the Closing Date. 25% of the remaining 338,282 shares will vest upon achievement of a certain milestone and 75% will vest on the first anniversary of the Closing Date, subject to the Reporting Person's continued service through such date; provided that, if the milestone is not achieved by the first anniversary of the Closing Date, all 338,282 shares shall be forfeited.

/s/ Mark Iwicki, attorney-in-fact 08/28/2025

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.